[
    {
        "contents": "data\\TR\\20161221-222133.news",
        "description": null,
        "guid": "yahoo_finance/3033774268",
        "link": "http://us.rd.yahoo.com/finance/external/xcapitalcube/rss/SIG=145u9bj26/*http://www.capitalcube.com/blog/index.php/trillium-therapeutics-inc-tr-ca-earnings-analysis-q3-2016-by-the-numbers-december-5-2016/",
        "pubDate": "Mon, 05 Dec 2016 16:40:21 GMT",
        "source": "data\\TR\\20161221.rss",
        "title": "Trillium Therapeutics, Inc. :TR-CA: Earnings Analysis: Q3, 2016 By the Numbers : December 5, 2016"
    },
    {
        "contents": "data\\TR\\20161221-222135.news",
        "description": "[Marketwired] - Trillium Therapeutics Inc. , a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today presented data from an ongoing study with its lead drug candidate, ...",
        "guid": "yahoo_finance/957973941",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-presents-initial-data-ongoing-170000629.html",
        "pubDate": "Sat, 03 Dec 2016 17:00:00 GMT",
        "source": "data\\TR\\20161221.rss",
        "title": "Trillium Presents Initial Data From Ongoing Study of TTI-621 in Patients With Advanced Hematologic Malignancies at the American Society of Hematology Annual Meeting"
    },
    {
        "contents": "data\\TR\\20161221-222137.news",
        "description": "[Marketwired] - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it will host a conference call and webcast at 8:30 ...",
        "guid": "yahoo_finance/3181295095",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-therapeutics-announces-conference-call-120000220.html",
        "pubDate": "Tue, 29 Nov 2016 12:00:00 GMT",
        "source": "data\\TR\\20161221.rss",
        "title": "Trillium Therapeutics Announces Conference Call and Webcast on December 5th to Discuss TTI-621 Data Presented at ASH"
    },
    {
        "contents": "data\\TR\\20161221-222139.news",
        "description": null,
        "guid": "yahoo_finance/3168224048",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://sg.finance.yahoo.com/news/trillium-reports-3q-loss-140733794.html",
        "pubDate": "Thu, 10 Nov 2016 14:07:33 GMT",
        "source": "data\\TR\\20161221.rss",
        "title": "Trillium reports 3Q loss"
    },
    {
        "contents": "data\\TR\\20161221-222141.news",
        "description": null,
        "guid": "yahoo_finance/686673768",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-reports-3q-loss-140733705.html",
        "pubDate": "Thu, 10 Nov 2016 14:07:33 GMT",
        "source": "data\\TR\\20161221.rss",
        "title": "Trillium reports 3Q loss"
    },
    {
        "contents": "data\\TR\\20161221-222143.news",
        "description": "[at noodls] - Additional clinical data from TTI-621 Phase 1a trial to be presented at 2016 American Society of Hematology (ASH) annual meeting in December Phase 1 trial with TTI-621 in solid tumors open for enrollment ...",
        "guid": "yahoo_finance/2297516602",
        "link": "http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128l9mrkd/*http://www.publicnow.com/view/635DD8C8783D892E9BA0FC1B12F829400CAFBB3E",
        "pubDate": "Thu, 10 Nov 2016 12:11:07 GMT",
        "source": "data\\TR\\20161221.rss",
        "title": "Trillium Reports Third Quarter 2016 Financial Results and Provides Corporate Update"
    },
    {
        "contents": "data\\TR\\20161221-222143.news",
        "description": "[Marketwired] - Trillium Therapeutics Inc. (TRIL)(TR.TO), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided a corporate update and reported financial results for the three and nine months ended September 30, 2016. \"We established a well-tolerated dose of TTI-621 in first part of the Phase 1a/1b trial in relapsed or refractory hematologic malignancies and look forward to presenting data at next month's ASH meeting. In November, the Phase 1b dose expansion cohorts in the TTI-621 trial in patients with advanced hematologic malignancies were opened for enrollment.",
        "guid": "yahoo_finance/2833267355",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-reports-third-quarter-2016-120000787.html",
        "pubDate": "Thu, 10 Nov 2016 12:00:00 GMT",
        "source": "data\\TR\\20161221.rss",
        "title": "Trillium Reports Third Quarter 2016 Financial Results and Provides Corporate Update"
    },
    {
        "contents": "data\\TR\\20161221-222144.news",
        "description": "[at noodls] - TORONTO, Nov. 3, 2016 - Trillium Therapeutics Inc. (NASDAQ: TRIL; TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, is scheduled to present ...",
        "guid": "yahoo_finance/2405892859",
        "link": "http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128s4g59i/*http://www.publicnow.com/view/600F367593083605BAA7341EA88BC10CE5404AF0",
        "pubDate": "Thu, 03 Nov 2016 11:07:26 GMT",
        "source": "data\\TR\\20161221.rss",
        "title": "Trillium Therapeutics Announces Investor and Scientific Presentation Schedule for Remainder of 2016"
    },
    {
        "contents": "data\\TR\\20161221-222144.news",
        "description": "[Marketwired] - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, is scheduled to present an update on the company's programs and progress ...",
        "guid": "yahoo_finance/3480191075",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-therapeutics-announces-investor-scientific-110000505.html",
        "pubDate": "Thu, 03 Nov 2016 11:00:00 GMT",
        "source": "data\\TR\\20161221.rss",
        "title": "Trillium Therapeutics Announces Investor and Scientific Presentation Schedule for Remainder of 2016"
    },
    {
        "contents": "data\\TR\\20161221-222146.news",
        "description": "[at noodls] - TORONTO, Nov. 2, 2016 - Trillium Therapeutics Inc. (NASDAQ: TRIL; TSX: TR), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, has advanced its novel ...",
        "guid": "yahoo_finance/3848807346",
        "link": "http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128gj51k2/*http://www.publicnow.com/view/A170FD1E9DB7080A80836BDB50FB07DC575F5F3E",
        "pubDate": "Wed, 02 Nov 2016 11:10:10 GMT",
        "source": "data\\TR\\20161221.rss",
        "title": "Trillium Therapeutics Advances TTI-621 Into Phase 1B Cohort Expansion Enrollment"
    },
    {
        "contents": "data\\TR\\20161221-222146.news",
        "description": "[Marketwired] - Trillium Therapeutics Inc. , a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, has advanced its novel investigational drug TTI-621, a SIRPa-IgG1 Fc fusion ...",
        "guid": "yahoo_finance/1332910865",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-therapeutics-advances-tti-621-110000882.html",
        "pubDate": "Wed, 02 Nov 2016 11:00:00 GMT",
        "source": "data\\TR\\20161221.rss",
        "title": "Trillium Therapeutics Advances TTI-621 Into Phase 1b Cohort Expansion Enrollment"
    },
    {
        "contents": "data\\TR\\20161221-222148.news",
        "description": null,
        "guid": "yahoo_finance/1409634109",
        "link": "http://us.rd.yahoo.com/finance/external/xcapitalcube/rss/SIG=147ose7u7/*http://www.capitalcube.com/blog/index.php/trillium-therapeutics-inc-tr-ca-earnings-analysis-q2-2016-by-the-numbers-september-16-2016/",
        "pubDate": "Fri, 16 Sep 2016 16:41:44 GMT",
        "source": "data\\TR\\20161221.rss",
        "title": "Trillium Therapeutics, Inc. :TR-CA: Earnings Analysis: Q2, 2016 By the Numbers : September 16, 2016"
    },
    {
        "contents": "data\\TR\\20161221-222153.news",
        "description": "[Marketwired] - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company has established an industry postdoctoral ...",
        "guid": "yahoo_finance/3273511851",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-therapeutics-introduces-industry-postdoctoral-110000999.html",
        "pubDate": "Wed, 31 Aug 2016 11:00:00 GMT",
        "source": "data\\TR\\20161221.rss",
        "title": "Trillium Therapeutics Introduces Industry Postdoctoral Fellowship Program"
    },
    {
        "contents": "data\\TR\\20161221-222154.news",
        "description": "[at noodls] - Toronto, Ontario, August 31, 2016 - Trillium Therapeutics Inc. (NASDAQ: TRIL; TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today ...",
        "guid": "yahoo_finance/4247710028",
        "link": "http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=1283bon7s/*http://www.publicnow.com/view/0CDDBDB90A821A609779D3C871295010A163F26A",
        "pubDate": "Tue, 30 Aug 2016 19:53:02 GMT",
        "source": "data\\TR\\20161221.rss",
        "title": "Trillium Therapeutics Introduces Industry Postdoctoral Fellowship Program"
    },
    {
        "contents": "data\\TR\\20161221-222155.news",
        "description": "[at noodls] - Toronto, Ontario, August 23, 2016 - Trillium Therapeutics Inc. (NASDAQ: TRIL; TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today ...",
        "guid": "yahoo_finance/2534487299",
        "link": "http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128krum2b/*http://www.publicnow.com/view/CE83C1926A8073643E0B662295F811F5C5EF48F1",
        "pubDate": "Tue, 23 Aug 2016 11:18:06 GMT",
        "source": "data\\TR\\20161221.rss",
        "title": "Trillium Therapeutics to Present at Investor and Scientific Conferences in September"
    },
    {
        "contents": "data\\TR\\20161221-222155.news",
        "description": "[Marketwired] - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled to present an update on ...",
        "guid": "yahoo_finance/2195596355",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-therapeutics-present-investor-scientific-110000254.html",
        "pubDate": "Tue, 23 Aug 2016 11:00:00 GMT",
        "source": "data\\TR\\20161221.rss",
        "title": "Trillium Therapeutics to Present at Investor and Scientific Conferences in September"
    },
    {
        "contents": "data\\TR\\20161221-222156.news",
        "description": "[at noodls] - Toronto, Ontario, August 17, 2016 - Trillium Therapeutics Inc. (NASDAQ: TRIL; TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today ...",
        "guid": "yahoo_finance/3211463728",
        "link": "http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=1283rpj20/*http://www.publicnow.com/view/578E365BE972DF950BC4353E7BBB210A4BB433E0",
        "pubDate": "Wed, 17 Aug 2016 11:11:05 GMT",
        "source": "data\\TR\\20161221.rss",
        "title": "Trillium Therapeutics Receives FDA Clearance to Proceed with TTI-621 in Clinical Trial Targeting Solid Tumors and Mycosis Fungoides"
    },
    {
        "contents": "data\\TR\\20161221-222157.news",
        "description": "[Marketwired] - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the US Food and Drug Administration has provided ...",
        "guid": "yahoo_finance/1148880496",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-therapeutics-receives-fda-clearance-110000353.html",
        "pubDate": "Wed, 17 Aug 2016 11:00:00 GMT",
        "source": "data\\TR\\20161221.rss",
        "title": "Trillium Therapeutics Receives FDA Clearance to Proceed With TTI-621 in Clinical Trial Targeting Solid Tumors and Mycosis Fungoides"
    },
    {
        "contents": "data\\TR\\20161221-222158.news",
        "description": null,
        "guid": "yahoo_finance/2964886933",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://sg.finance.yahoo.com/news/trillium-reports-2q-loss-115033085.html",
        "pubDate": "Fri, 12 Aug 2016 11:50:33 GMT",
        "source": "data\\TR\\20161221.rss",
        "title": "Trillium reports 2Q loss"
    },
    {
        "contents": "data\\TR\\20161221-222201.news",
        "description": null,
        "guid": "yahoo_finance/1152651927",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-reports-2q-loss-115033896.html",
        "pubDate": "Fri, 12 Aug 2016 11:50:33 GMT",
        "source": "data\\TR\\20161221.rss",
        "title": "Trillium reports 2Q loss"
    },
    {
        "contents": "data\\TR\\20161222-123312.news",
        "description": "[at noodls] - On track to report clinical data from TTI-621 program at the end of 2016 IND submitted to initiate a Phase 1 trial with TTI-621 in solid tumors Cash amounted to $60.1 million (CDN) as of June 30, 2016 ...",
        "guid": "yahoo_finance/1816664069",
        "link": "http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128urar7h/*http://www.publicnow.com/view/5840C4FD65ED74FF2FFC47ECC11CB6CF81C674F3",
        "pubDate": "Fri, 12 Aug 2016 11:21:04 GMT",
        "source": "data\\TR\\20161222.rss",
        "title": "Trillium Reports Second Quarter 2016 Financial Results"
    },
    {
        "contents": "data\\TR\\20161222-123312.news",
        "description": "[Marketwired] - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided a corporate update and reported financial results for the ...",
        "guid": "yahoo_finance/1347405217",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-reports-second-quarter-2016-110000958.html",
        "pubDate": "Fri, 12 Aug 2016 11:00:00 GMT",
        "source": "data\\TR\\20161222.rss",
        "title": "Trillium Reports Second Quarter 2016 Financial Results"
    },
    {
        "contents": "data\\TR\\20161222-123315.news",
        "description": "[at noodls] - Toronto, Ontario, June 7, 2016 - Trillium Therapeutics Inc. (NASDAQ: TRIL; TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, will present its ...",
        "guid": "yahoo_finance/2381990304",
        "link": "http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128827j93/*http://www.publicnow.com/view/A01EAC28CC44842C0C6024D9A0FBAB6E2BF8FBE9",
        "pubDate": "Tue, 07 Jun 2016 11:18:07 GMT",
        "source": "data\\TR\\20161222.rss",
        "title": "Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at European Hematology Association 21st Annual Congress"
    },
    {
        "contents": "data\\TR\\20161222-123315.news",
        "description": "[Marketwired] - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, will present its TTI-621 immune checkpoint inhibitor program at the European ...",
        "guid": "yahoo_finance/1446724680",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-therapeutics-announces-presentation-tti-110000757.html",
        "pubDate": "Tue, 07 Jun 2016 11:00:00 GMT",
        "source": "data\\TR\\20161222.rss",
        "title": "Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at European Hematology Association 21st Annual Congress"
    },
    {
        "contents": "data\\TR\\20161222-123316.news",
        "description": "[at noodls] - Toronto, Ontario, May 31, 2016 - Trillium Therapeutics Inc. (NASDAQ:TRIL; TSX: TR) a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced ...",
        "guid": "yahoo_finance/2213852964",
        "link": "http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128fevj1a/*http://www.publicnow.com/view/4DDC0C4FC77155DAE688412638FD438907843A28",
        "pubDate": "Tue, 31 May 2016 11:12:10 GMT",
        "source": "data\\TR\\20161222.rss",
        "title": "Trillium Announces Voting Results from The Annual And Special Meeting Of Shareholders"
    },
    {
        "contents": "data\\TR\\20161222-123316.news",
        "description": "[Marketwired] - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the voting results from its Annual and Special Meeting ...",
        "guid": "yahoo_finance/3110641129",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-announces-voting-results-annual-110000934.html",
        "pubDate": "Tue, 31 May 2016 11:00:00 GMT",
        "source": "data\\TR\\20161222.rss",
        "title": "Trillium Announces Voting Results From the Annual and Special Meeting of Shareholders"
    },
    {
        "contents": "data\\TR\\20161222-123318.news",
        "description": "[at noodls] - Toronto, Ontario, May 18, 2016 - Trillium Therapeutics Inc. (NASDAQ:TRIL; TSX: TR) a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, will present its ...",
        "guid": "yahoo_finance/1096564209",
        "link": "http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=12832p9av/*http://www.publicnow.com/view/351B7C22F590A369AD34C287273958471E5E47D8",
        "pubDate": "Wed, 18 May 2016 22:12:04 GMT",
        "source": "data\\TR\\20161222.rss",
        "title": "Trillium Therapeutics Announces Presentation On TTI-621 Immune Checkpoint Inhibitor Targeting CD47 At 2016 ASCO Annual Meeting"
    },
    {
        "contents": "data\\TR\\20161222-123318.news",
        "description": "[Marketwired] - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, will present its TTI-621 immune checkpoint inhibitor program at the Trials ...",
        "guid": "yahoo_finance/3405041823",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-therapeutics-announces-presentation-tti-210000544.html",
        "pubDate": "Wed, 18 May 2016 21:00:00 GMT",
        "source": "data\\TR\\20161222.rss",
        "title": "Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at 2016 ASCO Annual Meeting"
    },
    {
        "contents": "data\\TR\\20161222-123320.news",
        "description": "[at noodls] - TTI-621 Phase I clinical trial progressing according to plans Completed acquisition and integration of Fluorinov Cash amounted to $65.8 million as of March 31, 2016 Toronto, Ontario, May 13, 2016 - Trillium ...",
        "guid": "yahoo_finance/1153598000",
        "link": "http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128h59ckc/*http://www.publicnow.com/view/55F6B103E54190A40441CD023BA0360152B673B5",
        "pubDate": "Fri, 13 May 2016 11:28:09 GMT",
        "source": "data\\TR\\20161222.rss",
        "title": "Trillium Reports First Quarter 2016 Financial Results"
    },
    {
        "contents": "data\\TR\\20161222-123320.news",
        "description": null,
        "guid": "yahoo_finance/1742640402",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://sg.finance.yahoo.com/news/trillium-reports-1q-loss-112732301.html",
        "pubDate": "Fri, 13 May 2016 11:27:32 GMT",
        "source": "data\\TR\\20161222.rss",
        "title": "Trillium reports 1Q loss"
    },
    {
        "contents": "data\\TR\\20161222-123322.news",
        "description": null,
        "guid": "yahoo_finance/111989000",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-reports-1q-loss-112732622.html",
        "pubDate": "Fri, 13 May 2016 11:27:32 GMT",
        "source": "data\\TR\\20161222.rss",
        "title": "Trillium reports 1Q loss"
    },
    {
        "contents": "data\\TR\\20161222-123324.news",
        "description": "[Marketwired] - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided a corporate update and reported financial results for the ...",
        "guid": "yahoo_finance/980204997",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-reports-first-quarter-2016-110000178.html",
        "pubDate": "Fri, 13 May 2016 11:00:00 GMT",
        "source": "data\\TR\\20161222.rss",
        "title": "Trillium Reports First Quarter 2016 Financial Results"
    },
    {
        "contents": "data\\TR\\20161222-123325.news",
        "description": "[at noodls] - Toronto, Ontario - April 14, 2016 - Trillium Therapeutics Inc. (NASDAQ:TRIL; TSX: TR) an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced it will be ...",
        "guid": "yahoo_finance/3282638283",
        "link": "http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128nbtghr/*http://www.publicnow.com/view/2E2343438495F0E5894C3E8CACC13D20A044FBFC",
        "pubDate": "Thu, 14 Apr 2016 11:17:09 GMT",
        "source": "data\\TR\\20161222.rss",
        "title": "Trillium To Provide Update On CD47 Program At The 2016 American Association For Cancer Research Annual Meeting"
    },
    {
        "contents": "data\\TR\\20161222-123325.news",
        "description": "[Marketwired] - Trillium Therapeutics Inc. an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced it will be providing an update on its SIRPaFc immune checkpoint inhibitor ...",
        "guid": "yahoo_finance/1965585087",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-cd47-program-2016-american-110000849.html",
        "pubDate": "Thu, 14 Apr 2016 11:00:00 GMT",
        "source": "data\\TR\\20161222.rss",
        "title": "Trillium to Provide Update on CD47 Program at the 2016 American Association for Cancer Research Annual Meeting"
    },
    {
        "contents": "data\\TR\\20161222-123327.news",
        "description": "[at noodls] - Toronto, Ontario - April 12, 2016 - Trillium Therapeutics Inc. (NASDAQ:TRIL; TSX: TR) a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced ...",
        "guid": "yahoo_finance/2474847283",
        "link": "http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128f1gr92/*http://www.publicnow.com/view/3A79086B92C5630FB5D97415A76B2E1F25EADE67",
        "pubDate": "Tue, 12 Apr 2016 11:14:11 GMT",
        "source": "data\\TR\\20161222.rss",
        "title": "Trillium To Present At The 2016 Annual Needham Health Care Conference"
    },
    {
        "contents": "data\\TR\\20161222-123327.news",
        "description": "[Marketwired] - Trillium Therapeutics Inc. a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that Dr. Niclas Stiernholm, President and Chief Executive ...",
        "guid": "yahoo_finance/86700797",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-present-2016-annual-needham-110000548.html",
        "pubDate": "Tue, 12 Apr 2016 11:00:00 GMT",
        "source": "data\\TR\\20161222.rss",
        "title": "Trillium to Present at the 2016 Annual Needham Health Care Conference"
    },
    {
        "contents": "data\\TR\\20161222-123329.news",
        "description": "[at noodls] - Toronto, Ontario - March 23, 2016 - Trillium Therapeutics Inc. (NASDAQ:TRIL; TSX: TR) a clinical immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that ...",
        "guid": "yahoo_finance/918487741",
        "link": "http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128sl9jev/*http://www.publicnow.com/view/BBB0EA43559FC4FE6255E4171D6F226136630865",
        "pubDate": "Wed, 23 Mar 2016 11:32:25 GMT",
        "source": "data\\TR\\20161222.rss",
        "title": "Trillium Adopts Advance Notice By-law Amendment"
    },
    {
        "contents": "data\\TR\\20161222-123329.news",
        "description": null,
        "guid": "yahoo_finance/417492809",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-adopts-advance-notice-law-110000805.html",
        "pubDate": "Wed, 23 Mar 2016 11:00:00 GMT",
        "source": "data\\TR\\20161222.rss",
        "title": "Trillium Adopts Advance Notice By-Law Amendment"
    },
    {
        "contents": "data\\TR\\20161222-123331.news",
        "description": null,
        "guid": "yahoo_finance/1064519886",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-announces-3-4-million-140000258.html",
        "pubDate": "Thu, 10 Mar 2016 14:00:00 GMT",
        "source": "data\\TR\\20161222.rss",
        "title": "Trillium Announces a $3.4 Million Government Co-Funded Translational Research Program"
    },
    {
        "contents": "data\\TR\\20161222-123333.news",
        "description": null,
        "guid": "yahoo_finance/4029719200",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://sg.finance.yahoo.com/news/trillium-reports-4q-loss-232857800.html",
        "pubDate": "Wed, 09 Mar 2016 23:28:57 GMT",
        "source": "data\\TR\\20161222.rss",
        "title": "Trillium reports 4Q loss"
    },
    {
        "contents": "data\\TR\\20161222-123335.news",
        "description": "[at noodls] - Slide 1 The chemistry of better medicines Fluorinov Pharmaceuticals Non-Confidential Overview of Lead Programs January, 2016 This presentation may contain forward-looking statements, which reflect Fluorinov's/ ...",
        "guid": "yahoo_finance/610332798",
        "link": "http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128605gei/*http://www.publicnow.com/view/F04113FC673C81379B9AAC086DE35EC60601D53E",
        "pubDate": "Wed, 27 Jan 2016 14:07:06 GMT",
        "source": "data\\TR\\20161222.rss",
        "title": "Fluorinov Lead Programs"
    },
    {
        "contents": "data\\TR\\20161222-123335.news",
        "description": "[at noodls] - PowerPoint Presentation Q1/2016 This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking statements involve ...",
        "guid": "yahoo_finance/3384637256",
        "link": "http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=125ro0t2t/*http://www.noodls.com/view/761D2097ED170DE21B4F13AC9E8A03C052339D0F",
        "pubDate": "Tue, 12 Jan 2016 22:25:24 GMT",
        "source": "data\\TR\\20161222.rss",
        "title": "Q1 2016 Corporate Presentation"
    },
    {
        "contents": "data\\TR\\20161222-123335.news",
        "description": "[at noodls] - PowerPoint Presentation J.P. Morgan 34th Annual Healthcare Conference January 11-14, 2016 This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding ...",
        "guid": "yahoo_finance/2268536007",
        "link": "http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=125ac2dj2/*http://www.noodls.com/view/D281DC3601AA58EC06CFD869745A025871509133",
        "pubDate": "Tue, 12 Jan 2016 21:55:03 GMT",
        "source": "data\\TR\\20161222.rss",
        "title": "J.P. Morgan 34th Annual Healthcare Conference"
    },
    {
        "contents": "data\\TR\\20161222-123336.news",
        "description": "[at noodls] - Slide 1 SIRP\u03b1Fc, a CD47-Blocking Cancer Immunotherapeutic, Sensitizes Malignant B Cells to Macrophage-Mediated Destruction Natasja Nielsen Viller1,2, Saman Maleki Vareki2,3, Karen Dodge1, Hui Chen1, Vivian ...",
        "guid": "yahoo_finance/1151329907",
        "link": "http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=1257qgv5l/*http://www.noodls.com/view/AA75ED63A0CC9C29A6EDA212AA50D2D4B3107594",
        "pubDate": "Fri, 01 Jan 2016 06:14:08 GMT",
        "source": "data\\TR\\20161222.rss",
        "title": "ASH 2015 Presentation"
    },
    {
        "contents": "data\\TR\\20170131-090704.news",
        "description": "[Marketwired] - Trillium Therapeutics Inc. , a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has initiated dosing in its second Phase 1 clinical ...",
        "guid": "yahoo_finance/2366581874",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-therapeutics-doses-first-patient-120000606.html",
        "pubDate": "Tue, 31 Jan 2017 12:00:00 GMT",
        "source": "data\\TR\\20170131.rss",
        "title": "Trillium Therapeutics Doses First Patient With TTI-621 in Phase 1 Solid Tumor Trial"
    },
    {
        "contents": "data\\TR\\20170206-091215.news",
        "description": null,
        "guid": "yahoo_finance/2226157881",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-reports-2015-financial-operating-223031376.html",
        "pubDate": "Wed, 09 Mar 2016 22:30:31 GMT",
        "source": "data\\TR\\20170206.rss",
        "title": "Trillium Reports 2015 Financial and Operating Results"
    },
    {
        "contents": "data\\TR\\20170206-091217.news",
        "description": null,
        "guid": "yahoo_finance/3870563742",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-present-cowen-company-36th-120000881.html",
        "pubDate": "Tue, 08 Mar 2016 12:00:00 GMT",
        "source": "data\\TR\\20170206.rss",
        "title": "Trillium to Present at the Cowen and Company 36th Annual Health Care Conference"
    }
]